中国动脉硬化杂志2009，Vol.17Issue(7)：548-550,3.
氨氯地平治疗肾性高血压的疗效及安全性观察
The Study of Therapeutic Efficacy and Safety of Amlodipine in the Therapy for Renal Hypertension
唐东兴1
作者信息
- 1. 南华大学附属第二医院,湖南省衡阳市,421001
- 折叠
摘要
Abstract
Aim To study the the therapeutic efficacy and safety of amlodipine in the therapy for renal hyperten-sion. Methods 76 patients of renal hypenension with chronic renal failure were diagnosed to be treated with amlodip-ine for 12 weeks and compared with eaptopril. The initial dose was 5 nag Q12h, the maximal dose was 10 nag Q12h. the captopril dose was 25 mg Q 8h. The blood pressure, renal function,urea protein,heart rate,administration status and ad-verse reactions of the patients were observed during treating time. Results After 12 weeks of treatment,the blood pressure in amledipine group was reduced by ( 23.00±5.28 ) / ( 19.29 ± 2.31 ) mmHg. The total effective rate in amlo-dipine group 92.11% (70/76) respectively. The total adverse incidence rate in amlodipine group was 9.21% (7/76 ). While the blood pressure in captopril group was reduced by ( 11.90 ± 4.18 ) / ( 11.80 ± 2.29 ) mmHg. The total effective rate in captopril group was 61.67% ( 37/60 ) respectively. The total adverse incidence rate in captopril group were 16. 67% ( 10/60 ). There were no obvious changes of heart rate and renal function after treatment and no obvious adverse e-vent was showed in amlodipine group. Conclusion Amlodipin has a better efieacy and is safe in the therapy of chro-nic renal failure patients with renal hypertension.关键词
氨氯地平/肾性高血压/卡托普利/血管紧张素转化酶/血管紧张素Ⅱ/疗效/安全性Key words
Amlodipin/Renal Hypenension/Captopril/Angioteasin Converting Enzyme/Angioteusin Ⅱ/Therapeutic Efficacy/Safety分类
医药卫生引用本文复制引用
唐东兴..氨氯地平治疗肾性高血压的疗效及安全性观察[J].中国动脉硬化杂志,2009,17(7):548-550,3.
